FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2606-2617 June 12, 2008 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Seigel, D. PubMed Citation

Age-related macular degeneration is the leading cause of irreversible blindness in people 50 years of age or older in the developed world.^1,2 More than 8 million Americans have age-related macular degeneration, and the overall prevalence of advanced age-related macular degeneration is projected to increase by more than 50% by the year 2020.³ Recent advances in clinical research have led not only to a better understanding of the genetics and pathophysiology of age-related macular degeneration but also to new therapies designed to prevent and help treat it. This article reviews the clinical and histopathological features of age-related macular degeneration, as well . . . [Full Text of this Article]

Normal Retinal Architecture

Changes with Age

Pathophysiology of Age-Related Macular Degeneration

Classification, Clinical Features, and Untreated Disease Course

Risk Factors

Current Management

Antioxidant Supplementation in the Age-Related Eye Disease Study

Lifestyle and Dietary Modifications

Intravitreal Antiangiogenic Therapy

Ranibizumab and Bevacizumab

Ocular Photodynamic Therapy and Argon-Laser Photocoagulation Therapy

Vitreoretinal Surgery

Evolving Approaches

Combination Therapy

Genetic Approaches

Intraocular Devices

Conclusions

Source Information

From the Section of Ophthalmology and Visual Science, Department of Surgery, University of Chicago, Chicago (R.D.J., W.F.M.); and the Department of Ophthalmology, Harvard Medical School, Boston (J.W.M.).

Address reprint requests to Dr. Jager at University Retina and Macula Associates, 6320 W. 159th St., Suite A, Oak Forest, IL 60452, or at rjager@uretina.com.

Related Letters:

Age-Related Macular Degeneration
Seigel D., Herm R. J., Jager R. D., Mieler W. F., Miller J. W.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:1735-1736, Oct 16, 2008. Correspondence

This article has been cited by other articles:

• Mason, A. B., Hoh, J. (2009). CCR3: Shedding New Light on a Dark Problem?. J Mol Cell Biol 1: 17-19 [Abstract] [Full Text]  
• Zahn, G., Vossmeyer, D., Stragies, R., Wills, M., Wong, C. G., Loffler, K. U., Adamis, A. P., Knolle, J. (2009). Preclinical Evaluation of the Novel Small-Molecule Integrin {alpha}5{beta}1 Inhibitor JSM6427 in Monkey and Rabbit Models of Choroidal Neovascularization. Arch Ophthalmol 127: 1329-1335 [Abstract] [Full Text]  
• Ricci, F., Zampatti, S., D'Abbruzzi, F., Missiroli, F., Martone, C., Lepre, T., Pietrangeli, I., Sinibaldi, C., Peconi, C., Novelli, G., Giardina, E. (2009). Typing of ARMS2 and CFH in Age-Related Macular Degeneration: Case-Control Study and Assessment of Frequency in the Italian Population. Arch Ophthalmol 127: 1368-1372 [Abstract] [Full Text]  
• Franco, L. M., Zulliger, R., Wolf-Schnurrbusch, U. E. K., Katagiri, Y., Kaplan, H. J., Wolf, S., Enzmann, V. (2009). Decreased Visual Function after Patchy Loss of Retinal Pigment Epithelium Induced by Low-Dose Sodium Iodate. IOVS 50: 4004-4010 [Abstract] [Full Text]  
• Ni, J., Yuan, X., Gu, J., Yue, X., Gu, X., Nagaraj, R. H., Crabb, J. W., The Clinical Genomic and Proteomic AMD Study Group, (2009). Plasma Protein Pentosidine and Carboxymethyllysine, Biomarkers for Age-related Macular Degeneration. Mol. Cell. Proteomics 8: 1921-1933 [Abstract] [Full Text]  
• Gu, J., Pauer, G. J. T., Yue, X., Narendra, U., Sturgill, G. M., Bena, J., Gu, X., Peachey, N. S., Salomon, R. G., Hagstrom, S. A., Crabb, J. W., Clinical Genomic and Proteomic AMD Study Group, (2009). Assessing Susceptibility to Age-related Macular Degeneration with Proteomic and Genomic Biomarkers. Mol. Cell. Proteomics 8: 1338-1349 [Abstract] [Full Text]  
• Seigel, D., Herm, R. J., Jager, R. D., Mieler, W. F., Miller, J. W. (2008). Age-Related Macular Degeneration. NEJM 359: 1735-1736 [Full Text]